EGFR and lung adenocarcinoma: The development here of a mouse model to determine the effect of disrupting the binding of PI3K p110α to endogenous WT RAS proteins in EGFR-driven lung adenocarcinoma shows that this interaction is critical in tumors that are driven by upstream activators of the RAS pathways and not just those in which RAS is mutationally activated.